FBP26 Antibody

What is BP26 and why is it important in brucellosis detection?

BP26 is a 26-kDa periplasmic protein of Brucella that serves as a highly immunogenic antigen capable of eliciting strong antibody responses in infected animals. While it produces a somewhat delayed and weaker antibody response compared to Brucella O-polysaccharide (OPS) antigen, BP26 exhibits significantly higher specificity in brucellosis detection with minimal cross-reactivity with sera infected by other bacterial pathogens . BP26 is particularly valuable for detecting brucellosis caused by rough Brucella strains that lack OPS antigen on their surface, providing a critical diagnostic advantage in such cases .

How does BP26 contribute to DIVA (differentiation between infected and vaccinated animals) strategies?

BP26 plays a pivotal role in DIVA strategies because BP26 gene-deleted vaccines maintain their protective efficacy against wild-type Brucella strains while allowing serological differentiation between infected and vaccinated animals. In China, the BP26-mutant vaccine M5ΔBP26 has been authorized for preventing small ruminant brucellosis, highlighting the importance of developing detection methods targeting BP26 . When animals are vaccinated with BP26-deleted vaccines, they will not develop antibodies against BP26, while naturally infected animals will. This distinction allows researchers and veterinarians to differentiate between vaccination and actual infection using BP26-based diagnostic tests .

What types of BP26 antibodies are available for research purposes?

Research on BP26 antibodies has yielded several types of antibodies:

• Monoclonal antibodies (mAbs): These are produced using hybridoma technology and target specific epitopes on the BP26 protein. In recent research, 12 mAbs targeting BP26 were generated, with different epitope specificities .

• Polyclonal antibodies: Although not specifically mentioned in the search results, these are typically available for many antigens and represent mixtures of antibodies recognizing different epitopes.

The mAb designated as E10 has shown exceptional performance in cELISA assays, recognizing the epitope sequence QPIYVYPDDKNNLKEPTITGY and demonstrating high sensitivity across multiple animal species .

How does the sensitivity and specificity of BP26-based cELISA compare to iELISA for different animal species?

The E10 mAb-based competitive enzyme-linked immunosorbent assay (cELISA) has demonstrated superior performance compared to BP26-based indirect enzyme-linked immunosorbent assay (iELISA) in terms of accuracy, particularly for cattle and small ruminant brucellosis . Research data shows:

• For small ruminants: cELISA sensitivity reached 97.62% compared to only 64.29% for iELISA

• For cattle: E10-based cELISA achieved high sensitivity, detecting 100% of brucellosis-positive sera

• For canines: cELISA maintained 100% sensitivity in detecting brucellosis-positive sera

The comparative performance metrics across species are presented in the following table:

PPV: positive predictive value; NPV: negative predictive value

What are the critical epitopes in BP26 for antibody production and diagnostic applications?

Research has identified specific epitope regions on BP26 that are crucial for antibody recognition and diagnostic applications. Through epitope mapping studies using synthesized polypeptides, researchers have determined that:

• The mAb E10, which showed the highest diagnostic efficiency, recognizes the epitope sequence QPIYVYPDDKNNLKEPTITGY (peptide P3) .

• Three other mAbs (E4, E5, and E8) recognize the sequence AAAPDNSVPIAAGENSYNVSVNVVFE (peptide P6) .

• Eight other mAbs did not react to any of the tested polypeptides, suggesting they may recognize conformational epitopes rather than linear epitopes .

The complete epitope recognition profile for the 12 mAbs is presented in this table:

Understanding these epitope specificities is critical for developing improved diagnostic tests and for designing DIVA vaccines .

What factors influence the inhibition efficiency of anti-BP26 mAbs in cELISA applications?

The inhibition efficiency of anti-BP26 mAbs in cELISA varies significantly depending on several factors:

• Epitope specificity: The E10 mAb, which recognizes peptide P3 (QPIYVYPDDKNNLKEPTITGY), demonstrated significantly higher inhibition percentages compared to other mAbs across all tested animal species .

• Animal species: When using the same mAb (E10), the inhibition percentage varied across animal species. Using a threshold IP value of 40%, E10 showed inhibition rates of:

  • 38.64% for cattle brucellosis-positive sera

  • 57.14% for small ruminant brucellosis-positive sera

  • 100% for canine brucellosis-positive sera

• Test optimization: Optimal coating concentration of BP26 protein (10 μg/mL) and optimal serum volume (30 μL mixed with 70 μL of pre-diluted mAb at 0.875 μg/mL) significantly impact test performance .

The detailed inhibition percentage data for different mAbs across animal species is provided in the extensive Table 2 in the source material, demonstrating the marked superiority of E10 compared to other mAbs .

What is the optimal protocol for producing anti-BP26 monoclonal antibodies?

For producing anti-BP26 monoclonal antibodies, researchers should follow the traditional mouse hybridoma technique as described in recent literature:

• Antigen preparation: Purify recombinant BP26 protein to high homogeneity for immunization.

• Immunization: Immunize mice (typically BALB/c) with purified BP26 protein following a standard immunization schedule.

• Hybridoma production:

  • Isolate spleen cells from immunized mice

  • Fuse with myeloma cells using polyethylene glycol (PEG)

  • Culture in selective media (typically containing HAT - hypoxanthine, aminopterin, thymidine)

  • Screen hybridoma supernatants for reactivity against BP26

• Screening and selection: Select hybridomas producing antibodies with the desired specificity and binding characteristics. In the referenced research, this process yielded 12 hybridoma cell lines secreting mAbs reactive to BP26 .

• Production scale-up: Grow selected hybridomas in mouse ascites or in large-scale cell culture for antibody production.

• Purification: Purify mAbs using standard methods such as protein A/G affinity chromatography.

• Characterization: Determine isotype, specificity, and epitope recognition profile of the produced mAbs .

How should researchers optimize BP26-based cELISA for maximum sensitivity and specificity?

Optimization of BP26-based cELISA requires careful adjustment of multiple parameters:

• Coating concentration: The optimal coating concentration of BP26 protein has been determined to be 10 μg/mL .

• Antibody dilution: Pre-dilute the selected mAb (preferably E10) to the optimal concentration. Research indicates 0.875 μg/mL as an effective concentration .

• Sample volume optimization: Use 30 μL of test serum mixed with 70 μL of pre-diluted mAb before transferring to each microplate well .

• Cutoff determination: Establish species-specific cutoff values using ROC curve analysis. As demonstrated in research:

  • For cattle: <0.7283

  • For small ruminants: <0.8370

  • For canine: <0.6973

• Validation: Validate the assay using a panel of well-characterized positive and negative sera. The largest area under the ROC curve was observed for small ruminant sera (AUC = 0.9974), followed by cattle (AUC = 0.9934) and canine sera (AUC = 0.9814) .

• Quality control: Include appropriate positive and negative controls in each assay run to ensure consistent performance.

What are the recommended methods for epitope mapping of anti-BP26 monoclonal antibodies?

For effective epitope mapping of anti-BP26 monoclonal antibodies, researchers should consider the following methodological approach:

• Peptide synthesis: Generate overlapping synthetic peptides spanning the entire BP26 protein sequence. In the referenced research, six peptides (P1-P6) were synthesized based on the BP26 sequence .

• ELISA-based epitope mapping:

  • Coat microplates with individual synthetic peptides

  • Test reactivity of each mAb against these peptides

  • Identify peptides recognized by each mAb to locate the linear epitopes

• Confirmation strategies:

  • Peptide competition assays to verify specificity

  • Alanine scanning mutagenesis to identify critical residues within the epitope

  • Cross-reactivity testing with related proteins to assess specificity

• Structural analysis: If available, use protein structure information to map the identified linear epitopes onto the three-dimensional structure of BP26.

• Conformational epitope analysis: For mAbs that do not recognize linear peptides, consider advanced techniques such as hydrogen-deuterium exchange mass spectrometry (HDX-MS) or X-ray crystallography of antibody-antigen complexes.

This approach successfully identified the epitope of mAb E10 as QPIYVYPDDKNNLKEPTITGY, which could potentially serve as a diagnostic antigen for brucellosis .

How should researchers interpret discrepancies between BP26-based cELISA and iELISA results?

When researchers encounter discrepancies between BP26-based cELISA and iELISA results, they should consider several factors:

• Assay principle differences: cELISA and iELISA operate on different principles - competitive binding versus direct antigen detection, respectively. These fundamental differences can lead to varying results .

• Epitope accessibility: In cELISA, the monoclonal antibody competes with serum antibodies for binding to specific epitopes. If serum antibodies recognize different epitopes than the mAb, they won't compete effectively, potentially leading to false negatives .

• Species-specific variations: The data shows that the relative performance of cELISA versus iELISA varies by animal species. For small ruminants, cELISA sensitivity (97.62%) far exceeded iELISA (64.29%), suggesting that species-specific factors influence test performance .

• Analytical thresholds: Different cutoff values may lead to different interpretations of the same sample. Researchers should ensure they're using optimized cutoff values for each assay type and animal species .

• Resolution approach: When discrepancies occur, researchers should:

  • Test samples using a third method (e.g., Western blot)

  • Consider the clinical and epidemiological context

  • Look at the magnitude of the discrepancy (borderline versus clear difference)

  • Potentially sequence the BP26 gene from the infecting strain to check for mutations affecting antibody binding

How do BP26 antibody responses vary across different Brucella species and their hosts?

The BP26 antibody response shows variation across different Brucella species and their host animals:

• Host species differences: The research data demonstrates variable antibody responses to BP26 across different animal hosts:

  • Canine sera showed the most robust response, with 100% of positive samples having inhibition percentages (IPs) above 40% in the E10-based cELISA

  • Small ruminant sera showed moderate responses, with 57.14% of positive samples having IPs above 40%

  • Cattle sera showed lower responses, with 38.64% of positive samples having IPs above 40%

• Kinetics of response: BP26 generally elicits a delayed and somewhat weaker antibody response compared to Brucella O-polysaccharide (OPS) antigens, which affects detection timing in different species .

• Rough versus smooth Brucella strains: BP26 is particularly valuable for detecting infections with rough Brucella strains (lacking OPS) which may not be detected by conventional tests targeting LPS antigens .

• Antibody class variations: While not explicitly discussed in the search results, different animal species may produce varying proportions of different antibody classes (IgG, IgM, etc.) against BP26, which could affect test performance.

Researchers should consider these variations when designing diagnostic strategies and interpreting test results across different animal species and Brucella strains.

What statistical approaches are most appropriate for evaluating BP26 antibody-based diagnostic tests?

For proper evaluation of BP26 antibody-based diagnostic tests, researchers should employ the following statistical approaches: